Aurobindo Pharma Ltd has received approvals from the Medicines Control Council (MCC) to manufacture and market nine products in South Africa. These products are estimated to have a generic market size of ZAR 165 million in the local market
The company has received approvals for Auro-Lisinopril Co (CVS), Auro-Amlodipine (CVS), Auro-Finasterid (BPH), Zinoxime (anti-infective), Zolid (CNS), Yomax (anti-infective), Lazivir (ARV) Lisinozide (CVS) and Profina (BPH).